Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high
The shares of the company saw a spurt in volume by more than 2 times.
On Tuesday, one of the Top Gainers on BSE & NSE, shares of this multibagger pharma company hit 20 per cent upper circuit to Rs 16,544.75 per share from its previous closing of Rs 15,858.20 per share. The stock also made a new 52-week high is Rs 16,544.75 per share while its 52-week low is Rs 4,928 per share. The shares of the company saw a spurt in volume by more than 2 times. The company has not made any significant announcements of late. Hence, the rally in the share price could be driven purely by the market forces.
Two ace investors, Vijay Kedia and Mukul Agrawal owns 1.01 per cent (1,30,000 shares) and 3.12 per cent (4,00,000 shares) stake in the company, respectively as of September 2024. Therefore, at upper price band Mukul Agrawal gained Rs 1,10,29,80,000 and Vijay Kedia gained 35,84,68,500.
The stock name is Neuland Laboratories Ltd.
Recently, the company announced its Quarterly Results (Q2FY25) and half-yearly results (H1FY25). Total income decreased by 25.1 per cent to Rs 315.2 crore, EBITDA decreased by 53.2 per cent to Rs 65.7 crore and PAT decreased by 64.1 per cent to Rs 32 crore in Q2FY25 compared to Q2FY24. Total income decreased by 3.3 per cent to Rs 759.6 crore, EBITDA decreased by 18.9 per cent to Rs 194.3 crore and PAT decreased by 13.9 per cent to Rs 130.3 crore in H1FY25 compared to H1FY24.
DSIJ's DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, do download the service details here.
About the Company
Neuland Labs, a pioneer in API manufacturing, has been serving customers in nearly 80 countries for over four decades. With a strong focus on quality and compliance, they have developed and manufactured over 300 processes and 100 APIs. Their commitment to regulatory excellence is evident in their 978+ regulatory filings across major markets like the US, EU, and others. Their manufacturing facilities, inspected and approved by leading regulatory agencies such as the US FDA, adhere to stringent cGMP standards, ensuring product quality and safety. This robust track record, backed by certifications from various regulatory bodies worldwide, solidifies Neuland Labs' position as a trusted partner in the pharmaceutical industry.
The company has a market cap of over Rs 20,000 crore with a PE of 55x, an ROE of 27 per cent and an ROCE of 33 per cent. The stock gave multibagger returns of 200 per cent in 1 year, 850 per cent in 3 years and a whopping 3,000 per cent in 5 years.
Do you own shares of Neuland Laboratories Ltd.’s in your portfolio? Do let us know in the comments below
Disclaimer: The article is for informational purposes only and not investment advice.